The US Cystic Fibrosis Foundation has pledged up to $2.3m to Owlstone Medical for the development of a breath test for pseudomonas aeruginosa detection in patients with cystic fibrosis (CF).
P. aeruginosa infection is identified by a sputum culture in the clinic. However, the procedure is often inefficient given that treatments for CF often results in reduced airway mucus, which...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Medtech Insight for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?